-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From April 7 to April 13, about 81 companies in the two cities were investigated by the agency
.
The types of research institutions showed that securities companies conducted research on 76 companies; fund companies conducted research on 64 companies; and insurance companies conducted research on 46 companies
.
Among the survey respondents, pharmaceutical and biological companies are one of the areas of concern
.
And Tofflon has become the focus of the survey this week, with 317 institutions participating in the survey
.
It is understood that Tofflon's development strategy is internationalization, systematization and digital intelligence
.
It will strive to realize the vision of the delivery of smart pharmaceutical factories through systematization, internationalization, and digitalization, and is committed to growing into a global mainstream supplier of comprehensive pharmaceutical equipment
.
Judging from Tofflon's 2021 performance report, in 2021, Tofflon will grow rapidly in the bioengineering, medical equipment and consumables sectors.
Bioengineering will achieve a revenue of 906 million, a year-on-year increase of 305%.
A year-on-year increase of 104.
97%; injection revenue was 1.
381 billion yuan, and the proportion dropped to 33%; the proportion of overseas revenue continued to increase to nearly 25%; in 2021, the amortization of equity incentives will total 95.
24 million
.
The company's R&D expense ratio increased to 6.
79%, the number of R&D personnel increased to 677, accounting for 18%, and the number of employees in the company increased from 2,661 in 2020 to 3,672
.
In response to the competitive advantages of the company's medical equipment and consumables sector concerned by the organization during the investigation, Tofflon replied: the company has rich technical accumulation in bioreactors and liquid storage and distribution systems, cutting into disposable reactors in stirring, glycosylation It has universality in other aspects; in terms of media, fillers and other consumables, it wins with service advantages, and attaches great importance to new technologies such as continuous production; at the same time, the company has the advantage of internationalization, and international companies have commercialized procurement of disposable consumables, fillers, culture media , film package and other consumables are also on trial
.
In the field of medicine and biology, Betta Pharmaceuticals is also the focus of attention of institutions this week, with 130 institutions participating in the survey.
.
According to the data, Betta Pharmaceuticals is an enterprise with independent intellectual property rights innovative drug research and development as the core, integrating pharmaceutical research and development, production and marketing
.
In 2021, the company's operating income will increase by 20.
08% year-on-year, or about 2.
246 billion yuan
.
Data shows that in 2021, Betta Pharmaceuticals will invest 861 million yuan in R&D, accounting for 38.
32% of its operating income, of which capitalized R&D expenditures will account for 34.
24% of R&D investment
.
At present, the company has more than 40 products under development, of which more than 10 have entered clinical research, 2 have been declared for NDA, and 3 are undergoing phase III clinical trials, among which the global multi-center phase III clinical trial of the ensatinib hydrochloride project is in progress
.
In December 2021, the company's self-developed fourth-generation EGFR-TKI BPI-361175 was approved by the US FDA to enter clinical research, achieving a breakthrough in overseas research on independent innovative drugs
.
In addition to the above two companies, Xintian Pharmaceutical received 31 research institutions this week; Haier Biotechnology received 30 institutional research; Huakang Medical received 27 institutional research; Beilu Pharmaceutical received 13 institutional research
.
Sanxin Medical, Kexing Pharmaceutical, Baicheng Pharmaceutical, and China Resources Sanjiu were investigated by 5, 4, 3 and 2 institutions respectively
.
Among them, Xintian Pharmaceutical stated in the institutional survey that the company's operating income in 2021 will increase by 29.
15% year-on-year to 970 million yuan; the net profit attributable to shareholders of listed companies will increase by 35.
76% year-on-year to 101 million yuan
.
As for the expected production and approval time of the company's three new traditional Chinese medicine products concerned by institutions, as well as the performance contribution to the three-year doubling plan, Xintian Pharmaceutical said that the company has completed Longqin Penqiang Shu Granules, Ku'e Jieyin The Phase III clinical study of 3 new Chinese medicines, including Gel and Shuyutong Granules, is in the preparation period for the production of the project.
The company will make preparations according to relevant national policies and project conditions.
approval
.
The company's three-year performance doubling plan is mainly aimed at the sales of existing Chinese patent medicine products, and has not yet included new Chinese medicine products.
.
Haier Biology stated in the institutional survey that in 2021, the company's overseas market revenue will increase by 39.
34% year-on-year to 533.
0121 million yuan
.
In terms of overseas distribution, based on the competitiveness of products and solutions and the accumulated brand effect, the company's attractiveness to overseas high-quality partners has gradually increased.
As of the end of the reporting period, the total number of overseas distribution networks has exceeded 500, with 208 new and new in 2021.
At the same time, the company accelerated the process of localized sales, marketing, logistics and warehousing construction in Europe, America, South Asia and other regions, and built the localized ability to quickly gain insight and respond to user needs to ensure A good user experience drives the continuous improvement of competitiveness in overseas markets
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
.
The types of research institutions showed that securities companies conducted research on 76 companies; fund companies conducted research on 64 companies; and insurance companies conducted research on 46 companies
.
Among the survey respondents, pharmaceutical and biological companies are one of the areas of concern
.
And Tofflon has become the focus of the survey this week, with 317 institutions participating in the survey
.
It is understood that Tofflon's development strategy is internationalization, systematization and digital intelligence
.
It will strive to realize the vision of the delivery of smart pharmaceutical factories through systematization, internationalization, and digitalization, and is committed to growing into a global mainstream supplier of comprehensive pharmaceutical equipment
.
Judging from Tofflon's 2021 performance report, in 2021, Tofflon will grow rapidly in the bioengineering, medical equipment and consumables sectors.
Bioengineering will achieve a revenue of 906 million, a year-on-year increase of 305%.
A year-on-year increase of 104.
97%; injection revenue was 1.
381 billion yuan, and the proportion dropped to 33%; the proportion of overseas revenue continued to increase to nearly 25%; in 2021, the amortization of equity incentives will total 95.
24 million
.
The company's R&D expense ratio increased to 6.
79%, the number of R&D personnel increased to 677, accounting for 18%, and the number of employees in the company increased from 2,661 in 2020 to 3,672
.
In response to the competitive advantages of the company's medical equipment and consumables sector concerned by the organization during the investigation, Tofflon replied: the company has rich technical accumulation in bioreactors and liquid storage and distribution systems, cutting into disposable reactors in stirring, glycosylation It has universality in other aspects; in terms of media, fillers and other consumables, it wins with service advantages, and attaches great importance to new technologies such as continuous production; at the same time, the company has the advantage of internationalization, and international companies have commercialized procurement of disposable consumables, fillers, culture media , film package and other consumables are also on trial
.
In the field of medicine and biology, Betta Pharmaceuticals is also the focus of attention of institutions this week, with 130 institutions participating in the survey.
.
According to the data, Betta Pharmaceuticals is an enterprise with independent intellectual property rights innovative drug research and development as the core, integrating pharmaceutical research and development, production and marketing
.
In 2021, the company's operating income will increase by 20.
08% year-on-year, or about 2.
246 billion yuan
.
Data shows that in 2021, Betta Pharmaceuticals will invest 861 million yuan in R&D, accounting for 38.
32% of its operating income, of which capitalized R&D expenditures will account for 34.
24% of R&D investment
.
At present, the company has more than 40 products under development, of which more than 10 have entered clinical research, 2 have been declared for NDA, and 3 are undergoing phase III clinical trials, among which the global multi-center phase III clinical trial of the ensatinib hydrochloride project is in progress
.
In December 2021, the company's self-developed fourth-generation EGFR-TKI BPI-361175 was approved by the US FDA to enter clinical research, achieving a breakthrough in overseas research on independent innovative drugs
.
In addition to the above two companies, Xintian Pharmaceutical received 31 research institutions this week; Haier Biotechnology received 30 institutional research; Huakang Medical received 27 institutional research; Beilu Pharmaceutical received 13 institutional research
.
Sanxin Medical, Kexing Pharmaceutical, Baicheng Pharmaceutical, and China Resources Sanjiu were investigated by 5, 4, 3 and 2 institutions respectively
.
Among them, Xintian Pharmaceutical stated in the institutional survey that the company's operating income in 2021 will increase by 29.
15% year-on-year to 970 million yuan; the net profit attributable to shareholders of listed companies will increase by 35.
76% year-on-year to 101 million yuan
.
As for the expected production and approval time of the company's three new traditional Chinese medicine products concerned by institutions, as well as the performance contribution to the three-year doubling plan, Xintian Pharmaceutical said that the company has completed Longqin Penqiang Shu Granules, Ku'e Jieyin The Phase III clinical study of 3 new Chinese medicines, including Gel and Shuyutong Granules, is in the preparation period for the production of the project.
The company will make preparations according to relevant national policies and project conditions.
approval
.
The company's three-year performance doubling plan is mainly aimed at the sales of existing Chinese patent medicine products, and has not yet included new Chinese medicine products.
.
Haier Biology stated in the institutional survey that in 2021, the company's overseas market revenue will increase by 39.
34% year-on-year to 533.
0121 million yuan
.
In terms of overseas distribution, based on the competitiveness of products and solutions and the accumulated brand effect, the company's attractiveness to overseas high-quality partners has gradually increased.
As of the end of the reporting period, the total number of overseas distribution networks has exceeded 500, with 208 new and new in 2021.
At the same time, the company accelerated the process of localized sales, marketing, logistics and warehousing construction in Europe, America, South Asia and other regions, and built the localized ability to quickly gain insight and respond to user needs to ensure A good user experience drives the continuous improvement of competitiveness in overseas markets
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
